Literature DB >> 2511228

Monitoring the acute phase response: comparison of tumour necrosis factor (cachectin) and C-reactive protein responses in inflammatory and infectious diseases.

C P Maury1.   

Abstract

The relation between the inflammatory cytokine tumour necrosis factor-alpha (TNF or cachectin), which induces acute phase responses, and an established acute phase protein, C-reactive protein, was studied in various infectious and inflammatory diseases in man. All cases with very high serum concentrations of C-reactive protein (150 to 400 mg/l; normal reference value less than 10 mg/l) also had raised serum concentrations of TNF (53 to 705 ng/l; normal reference value less than 40 ng/l). In 19 out of 91 (21%) of the cases, however, a raised TNF concentration without correspondingly raised C-reactive protein concentration was also noted. Conversely, in 23 out of 106 (22%) cases raised C-reactive protein was observed in the absence of a raised TNF concentration. The ratios were high in allograft rejection and low in myocardial infarction and Kawasaki's disease. The highest mean concentration of circulating TNF was found in bacterial infections, graft rejection, and myocardial infarction. It is concluded that although high C-reactive protein concentrations are usually accompanied by raised TNF concentrations, there are pronounced relative variations in the serum concentrations of these proteins in various disease states, suggesting that there may be independent, disease specific regulatory pathways for TNF and C-reactive protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511228      PMCID: PMC501867          DOI: 10.1136/jcp.42.10.1078

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  31 in total

1.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

2.  Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation.

Authors:  K P McAdam; R J Elin; J D Sipe; S M Wolff
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

3.  Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

Authors:  P B Chapman; T J Lester; E S Casper; J L Gabrilove; G Y Wong; S J Kempin; P J Gold; S Welt; R S Warren; H F Starnes
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

4.  Radioimmunoassay of tumor necrosis factor in serum.

Authors:  A M Teppo; C P Maury
Journal:  Clin Chem       Date:  1987-11       Impact factor: 8.327

5.  Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha.

Authors:  G Ramadori; J Van Damme; H Rieder; K H Meyer zum Büschenfelde
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

6.  Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome.

Authors:  J Lähdevirta; C P Maury; A M Teppo; H Repo
Journal:  Am J Med       Date:  1988-09       Impact factor: 4.965

7.  Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes.

Authors:  J V Castell; M J Gómez-Lechón; M David; T Hirano; T Kishimoto; P C Heinrich
Journal:  FEBS Lett       Date:  1988-05-23       Impact factor: 4.124

8.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

9.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.

Authors:  P F Piguet; G E Grau; B Allet; P Vassalli
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells.

Authors:  S S Sung; L K Jung; J A Walters; W Chen; C Y Wang; S M Fu
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  7 in total

1.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Tumor necrosis factor alpha in children with sickle cell disease in stable condition.

Authors:  S Kuvibidila; R Gardner; D Ode; L Yu; G Lane; R P Warrier
Journal:  J Natl Med Assoc       Date:  1997-09       Impact factor: 1.798

3.  Comparison of pediatric scoring systems for mortality in septic patients and the impact of missing information on their predictive power: a retrospective analysis.

Authors:  Christian Niederwanger; Thomas Varga; Tobias Hell; Daniel Stuerzel; Jennifer Prem; Magdalena Gassner; Franziska Rickmann; Christina Schoner; Daniela Hainz; Gerard Cortina; Benjamin Hetzer; Benedikt Treml; Mirjam Bachler
Journal:  PeerJ       Date:  2020-10-05       Impact factor: 2.984

4.  Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis.

Authors:  C Fabris; M Pirisi; G Soardo; E Falleti; F Pezzetta; D Vitulli; P Toniutto; N Bortolotti; F Gonano; E Bartoli
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Inflammatory and coagulatory parameters linked to survival in critically ill children with sepsis.

Authors:  Christian Niederwanger; Mirjam Bachler; Tobias Hell; Caroline Linhart; Andreas Entenmann; Agnes Balog; Katharina Auer; Petra Innerhofer
Journal:  Ann Intensive Care       Date:  2018-11-16       Impact factor: 6.925

6.  Response patterns of routinely measured inflammatory and coagulatory parameters in sepsis.

Authors:  Mirjam Bachler; Tobias Hell; Lukas Schausberger; Christine Schlömmer; Volker Schäfer; Marlies Liebensteiner; Katharina Schäffler; Bettina Schenk; Dietmar Fries; Petra Innerhofer; Christian Niederwanger
Journal:  PeerJ       Date:  2019-06-21       Impact factor: 2.984

7.  [Assessment of the severity of the condition of patients admitted to intensive care by measuring CRP].

Authors:  Jackson Djuma; Prosper Kalenga; Costa Kazadi; Diego Orbegozo; Jean Louis Vincent
Journal:  Pan Afr Med J       Date:  2015-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.